TGRX 326
Alternative Names: TGRX-326Latest Information Update: 24 Aug 2026
At a glance
- Originator Shenzhen TargetRx
- Developer Shenzhen TargetRx; Sun Yat-Sen University Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
Most Recent Events
- 02 Jun 2026 Updated efficacy and adverse event data from a phase II trial in Non-small cell lung cancer presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)
- 02 Sep 2024 TGRX 326 licensed to Simcere Zaiming in Mainland China
- 21 Jul 2024 Shenzhen TargetRx completes a phase I pharmacokinetics trial (In Volunteers) in China (PO) (NCT06438367)